171178-48-6

Basic information

• Product Name: 4,6-DICHLOROPYRIDO[3,4-D]PYRIMIDINE
• Synonyms: 4,6-DICHLOROPYRIDO[3,4-D]PYRIMIDINE;Pyrido[3,4-d]pyrimidine,4,6-dichloro-
• CAS NO: 171178-48-6
• Molecular Formula: C₇H₃Cl₂N₃
• Molecular Weight: 200.0248
• Mol File: 171178-48-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 340.821 °C at 760 mmHg
• Flash Point: 190.498 °C
• Appearance: /
• Density: 1.573 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.682
• PKA: 0.21±0.30(Predicted)
• CAS DataBase Reference: 4,6-DICHLOROPYRIDO[3,4-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-DICHLOROPYRIDO[3,4-D]PYRIMIDINE(171178-48-6)
• EPA Substance Registry System: 4,6-DICHLOROPYRIDO[3,4-D]PYRIMIDINE(171178-48-6)

Safety Data

• Hazardous Substances Data: 171178-48-6(Hazardous Substances Data)

Usage

General Description

4,6-Dichloropyrido[3,4-d]pyrimidine is a chemical compound with the molecular formula C7H3Cl2N3. It is an organic compound that is primarily used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 4,6-DICHLOROPYRIDO[3,4-D]PYRIMIDINE is a pyrido-pyrimidine derivative and is classified as a chlorinated heterocyclic compound. 4,6-Dichloropyrido[3,4-d]pyrimidine is often used as a building block in the production of various drugs and pesticides. It is also known for its potential biological activity and is being studied for its potential therapeutic applications.

InChI:InChI=1/C7H3Cl2N3/c8-6-1-4-5(2-10-6)11-3-12-7(4)9/h1-3H

Upstream product

• 1072-98-6 5-chloro-2-pyridylamine 
• 5350-93-6 6-Chloro-pyridin-3-ylamine 
• 171178-47-5 6-chloro-pyrido[3,4-d]pyrimidin-4-one 
• 75-09-2 dichloromethane 
• 171178-46-4 5-[N-(tert-butoxycarbonyl)amino]-2-chloropyridine-4-carboxylic acid 
• 171178-45-3 tert-butyl (6-chloropyridin-3-yl)carbamate 
• 58483-95-7 5‐amino‐2‐chloropyridine‐4‐carboxylic acid 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 171178-47-5 6-chloro-3H-pyrido[3,4-d]pyrimidin-4-one 

Downstream Products

• 202272-68-2 GW2974 
• 202273-09-4 (1-benzyl-1H-indazol-5-yl)-(6-chloropyrido[3,4-d]pyrimidin-4-yl)-amine hydrochloride 
• 230955-62-1 (6-chloropyrido[3,4-d]pyrimidin-4-yl)-(4-(3-fluorobenzyloxy)-phenyl)-amine 
• 1594729-07-3 6-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-4-amine 
• 1240349-47-6 C₂₃H₁₇ClF₃N₅O₂ 
• 287193-31-1 (6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-(3-methyl-4-phenoxy-phenyl)-amine hydrochloride 
• 307326-86-9 6-Chloro-4-(4-phenoxyanilino)pyrido[3,4-d]pyrimidine 
• 202272-67-1 (1-benzyl-1H-indazol-5-yl)-(6-chloropyrido[3,4-d]pyrimidin-4-yl)-amine 
• 202272-97-7 (1-Benzyl-1H-indol-5-yl)-(6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine 
• 202272-71-7 (2-benzyl-1H-benzimidazol-5-yl)-(6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine 

Relevant articles and documents

Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold

In the present study, a new class of compounds containing pyrido[3,4-d]pyrimidine scaffold with an acrylamide moiety was designed as irreversible EGFR-TKIs to overcome acquired EGFR-T790M resistance. The most promising compound 25h inhibited HCC827 and H1975 cells growth with the IC50 values of 0.025 μM and 0.49 μM, respectively. Meanwhile, 25h displayed potent inhibitory activity against the EGFRL858R (IC50 = 1.7 nM) and EGFRL858R/T790M (IC50 = 23.3 nM). 25h could suppress EGFR phosphorylation in HCC827 and H1975 cell lines and significantly induce the apoptosis of HCC827 cells. Additionally, compound 25h could remarkably inhibit cancer growth in established HCC827 xenograft mouse model at 50 mg/kg in vivo. These results indicated that the 2,4-disubstituted 6-(5-substituted pyridin-2-amino)pyrido[3,4-d]pyrimidine derivatives can serve as effective EGFR inhibitors and potent anticancer agents.

HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS

The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

PYRIMIDO [5,4-D] PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES

The present invention encompasses compounds of general formula (1), wherein the groups R1 to R4, X1, X2, X3, X4, X5, Q, L1 and L2 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, as well as pharmaceutical preparations and formulations of these compounds.